Virtu Financial LLC Takes $41,000 Position in The Oncology Institute, Inc. (NASDAQ:TOI)

Virtu Financial LLC bought a new stake in The Oncology Institute, Inc. (NASDAQ:TOI – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 131,759 shares of the company’s stock, valued at approximately $41,000.

Virtu Financial LLC owned 0.17% of Oncology Institute as of its most recent SEC filing. Other institutional investors and hedge funds have also modified their holdings of the company.



Tiff Advisory Services LLC boosted its stake in Oncology Institute by 13.2% during the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock worth $921,000 after purchasing an additional 346,256 shares during the last quarter.

FreeGulliver LLC grew its stake in Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after acquiring an additional 412,578 shares in the last quarter.

Finally, HighTower Advisors LLC raised its holdings in Oncology Institute by 190.8% in the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after acquiring an additional 53,382 shares during the last quarter.

Hedge funds and other institutional investors own 36.86% of the company’s stock. Oncology Institute Trading Up 10.

5 %Shares of Oncology Institute stock opened at $1.26 on Wednesday. The Oncology Institute, Inc.

has a 1-year low of $0.13 and a 1-year high of $1.63.

The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.

27. The stock has a market cap of $95.20 million, a P/E ratio of -1.

62 and a beta of 0.41. The stock’s 50 day simple moving average is $0.

88 and its 200-day simple moving average is $0.49. Oncology Institute (NASDAQ:TOI – Get Free Report) last posted its quarterly earnings results on Monday, March 24th.

The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.

06). The firm had revenue of $100.27 million during the quarter, compared to analysts’ expectations of $109.

15 million. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.

83%. Insider Activity at Oncology InstituteIn other news, Director Mark L. Pacala bought 90,562 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th.

The shares were purchased at an average price of $1.04 per share, with a total value of $94,184.48.

Following the purchase, the director now owns 224,971 shares in the company, valued at approximately $233,969.84. The trade was a 67.

38 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have purchased 122,258 shares of company stock worth $127,148.

Company insiders own 9.50% of the company’s stock. Oncology Institute Profile (Free Report)The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States.

The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.Featured StoriesFive stocks we like better than Oncology InstituteDividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyInvesting in Commodities: What Are They? How to Invest in ThemAmazon Falls Back to a Key Support Line: Here’s How to Play ItTop Biotech Stocks: Exploring Innovation OpportunitiesBuffett Trims Equities, But Still Keeps Buying This Stock.